Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: A proof-of-concept study

Radiology

Volumn 271, Issue 3, 2014, Pages 739-747

  Bastati, Nina ^a   Feier, Diana ^a   Wibmer, Andreas ^a   Traussnigg, Stefan ^b   Balassy, Csilla ^a   Tamandl, Dietmar ^a   Einspieler, Henrik ^a   Wrba, Friedrich ^c   Trauner, Michael ^b   Herold, Christian ^a   Ba Ssalamah, Ahmed ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Department of Internal Medicine III ^*  (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GADOXETIC ACID; GAMMA GLUTAMYLTRANSFERASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84901660263     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14131890     Document Type: Article

References (37)

1. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007;17(11):863-869.
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55(7):434-438.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346(16):1221-1231.
4. Evans CD, Oien KA, MacSween RN, Mills PR. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol 2002;55(9):689-692.
5. Nascimbeni F, Pais R, Bellentani S, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013;59(4):859-871.
6. Reid AE. Nonalcoholic steatohepatitis. Gas-troenterology 2001;121(3):710-723.
7. Afdhal NH, Curry M. Technology evaluation: a critical step in the clinical utilization of novel diagnostic tests for liver fbrosis. J Hepatol 2007;46(4):543-545.
8. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010;55(3):560-578.
9. Lydatakis H, Hager IP, Kostadelou E, Mp-ousmpoulas S, Pappas S, Diamantis I. Non-invasive markers to predict the liver fbrosis in non-alcoholic fatty liver disease. Liver Int 2006;26(7):864-871.
10. Lall CG, Aisen AM, Bansal N, Sandrasegaran K. Nonalcoholic fatty liver disease. AJR Am J Roentgenol 2008;190(4):993-1002.
11. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatol-ogy 2011;53(3):810-820.
12. Bedossa P, Poitou C, Veyrie N, et al. Histo-pathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012;56(5):1751-1759.
13. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344(7):495-500.
14. Gaidos JK, Hillner BE, Sanyal AJ. A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis. Liver Int 2008; 28(5):650-658.
15. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123(3):745-750.
16. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantifcation of liver steato-sis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009;51(3): 433-445.
17. Guiu B, Petit JM, Loffroy R, et al. Quanti-fcation of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. Radiology 2009;250(1):95-102.
18. Sevastianova K, Hakkarainen A, Kotronen A, et al. Nonalcoholic fatty liver disease: detection of elevated nicotinamide ade-nine dinucleotide phosphate with in vivo 3.0-T 31P MR spectroscopy with proton decoupling. Radiology 2010;256(2):466-473.
19. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011;259(3):749-756.
20. Asanuma T, Ono M, Kubota K, et al. Super paramagnetic iron oxide MRI shows defective Kupffer cell uptake function in non-alcoholic fatty liver disease. Gut 2010;59(2): 258-266.
21. Sonoda A, Nitta N, Ohta S, et al. The possibility of differentiation between nonalcoholic steatohepatitis and fatty liver in rabbits on Gd-EOB-DTPA-enhanced open-type MRI scans. Acad Radiol 2011;18(4): 525-529.
22. Tsuda N, Okada M, Murakami T. Potential of gadolinium-ethoxybenzyl- diethylenetri-amine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steato-hepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 2007; 42(4):242-247.
23. Tsuda N, Okada M, Murakami T. New proposal for the staging of nonalcoholic steato-hepatitis: evaluation of liver fbrosis on Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 2010; 73(1):137-142.
24. Feier D, Balassy C, Bastati N, Stift J, Ba-dea R, Ba-Ssalamah A. Liver fbrosis: his-topathologic and biochemical infuences on diagnostic effcacy of hepatobiliary contrast-enhanced MR imaging in staging. Radiology 2013;269(2):460-468.
25. Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 2009;30(5):1042-1046.
26. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41(6):1313-1321.
27. Wibmer A, Aliya Q, Steininger R, et al. Liver transplantation: impaired biliary excretion of gadoxate is associated with an inferior 1-year retransplantation-free survival. Invest Radiol 2012;47(6):353-358.
28. Frydrychowicz A, Jedynak AR, Kelcz F, Nagle SK, Reeder SB. Gadoxetic acid-enhanced T1-weighted MR cholangiography in primary sclerosing cholangitis. J Magn Re-son Imaging 2012;36(3):632-640.
29. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010;16(42):5286-5296.
30. Chen BB, Hsu CY, Yu CW, et al. Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fbrosis in chronic hepatitis patients. Eur Radiol 2012;22(1):171-180.
31. Kitao A, Zen Y, Matsui O, et al. Hepatocel-lular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging-correlation with molecular transporters and histopathologic features. Radiology 2010;256(3):817-826.
32. Sebastiani G, Vario A, Guido M, Alberti A. Performance of noninvasive markers for liver fbrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat 2008; 15(3):212-218.
33. Krishnamurthy HA. The serum gamma glu-tamyl transpeptidase-a non invasive diagnostic bio marker of chronic anicteric non alcoholic liver diseases. J Clin Diagn Res 2013; 7(4):691-694.
34. Watanabe H, Kanematsu M, Goshima S, et al. Staging hepatic fbrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging-preliminary observations. Radiology 2011;259(1):142-150.
35. Tajima T, Takao H, Akai H, et al. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaace-tic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr 2010;34(3): 362-366.
36. Nilsson H, Blomqvist L, Douglas L, et al. Gd-EOB-DTPA-enhanced MRI for the assessment of liver function and volume in liver cirrhosis. Br J Radiol 2013;86(1026): 20120653.
37. Tsuda N, Matsui O. Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi-gadoxetic acid-enhanced MR imaging. Radiology 2010; 256(3):767-773.